Tag: Molecular Partners

September 9, 2019 Off

Allergan, Molecular Partners move forward with its quarterly dosed anti-VEGF treatment

Allergan and Molecular Partners’s Abicipar pegol DARPin therapy was accepted by FDA in the USA, and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA), for patients with neovascular (wet) age-related macular degeneration (nAMD).

April 2, 2019 Off

Molecular Partners, Allergan to file abicipar BLA in USA in the first half of 2019

By Dino Mustafić

Allergan and Molecular Partners revealed Tuesday the topline safety results from MAPLE, study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process, which showed lower incidence and type of IOI.